Before accessing this site, you agree that you have read and agree to the disclaimers at the bottom of this page.
Stock Charts AI Power Rank: 9.3
Power Rank trend -> Rising
Industry: Drug Manufacturers - General
Follow @stockchartsai on TwitterIn the past 20 trading days, GILD has been trading in a range between $98.38 and $89.88 (gray range band). Red lines on the chart represent key resistance levels and Green lines represent key support levels. As the price moves above the lines you will notice they turn green and red if price moves below a line.
GILD is breaking above top of the recent 20 day range at $98.38 and appears that it could have some more upside. If it enters a yellow zone the trend may be faltering - consider exiting or taking profits. If it enters a red zone on the chart we would exit the position.
Gilead Sciences Inc $GILD entered a Green zone 18 days ago on the AI powered stock chart. Wall Street analysts have an AVG target price $99.9585, a potential upside of 4.08% from the recent price of 96.04. The stock is trading 4.65% (potential upside) below its 52 week high of $100.51 and 59.43 % (potential downside) above its 52 week low of $60.24 - based on the recent price.
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.
Gilead Ups 2025 Outlook, Eyes Lenacapavir Launch For HIV Prevention Tuesday, Gilead Sciences Inc GILD reported fourth-quarter 2024 adjusted EPS of $1.90, beating the consensus of $1.70. Source: Benzinga Wed, 12 Feb 2025 15:22:27 -0500 Sentiment: Positive |
Why Gilead Sciences Stock Is Jumping Today Shares of Gilead Sciences (GILD 7.14%) were jumping 7.9% higher on Wednesday at 11:34 a.m. The solid gain came after the big biotech company announced its 2024 fourth-quarter and full-year financial results following market close on Tuesday. Source: The Motley Fool Wed, 12 Feb 2025 12:21:07 -0500 Sentiment: Positive |
Gilead Sciences (GILD) is a Top-Ranked Value Stock: Should You Buy? The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage. Source: Zacks Investment Research Wed, 12 Feb 2025 10:46:39 -0500 Sentiment: Positive |
GILD Stock Up on Q4 Earnings and Sales Beat & Upbeat '25 Guidance Gilead Sciences' Q4 earnings and sales beat estimates on higher HIV, oncology and liver disease drug sales. The stock is trading up. Source: Zacks Investment Research Wed, 12 Feb 2025 09:31:10 -0500 Sentiment: Positive |
Pharma Stock Surges on Beat-and-Raise Shares of Gilead Sciences Inc (NASDAQ:GILD) are up 4% in premarket trading, after the company delivered a strong fourth-quarter earnings beat. Source: Schaeffers Research Wed, 12 Feb 2025 09:06:26 -0500 Sentiment: Positive |
Stock Analyzed Each Night
Easily Upload Track Your Stocks
See Lists of Stocks Starting New Trends
The information contained on this website is solely for educational purposes, and does not constitute investment advice. The risk of trading in securities markets can be substantial. By accessing this site, you agree we are not liable, whether in contract, tort (including negligence) or otherwise, in respect of any damage, expense or other loss you may suffer arising out of such information or any reliance you may place upon such information from this site. Stocks, Futures and options trading has large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the stock, futures and options markets. Don't trade with money you can't afford to lose. This website is neither a solicitation nor an offer to Buy/Sell futures or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this website. The past performance of any trading system or methodology is not necessarily indicative of future results. Individual results may vary, and testimonials are not claimed to represent typical results. All testimonials are by real people, and may not reflect the typical purchaser’s experience, and are not intended to represent or guarantee that anyone will achieve the same or similar results. HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR-OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY, SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.